Market Closed -
Nasdaq
04:00:00 2024-07-11 pm EDT
|
5-day change
|
1st Jan Change
|
2.58
USD
|
+9.32%
|
|
+13.66%
|
-22.29%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
866.6
|
302.5
|
198.7
|
218
|
-
|
-
|
Enterprise Value (EV)
1 |
653.7
|
228.5
|
198.7
|
218
|
218
|
218
|
P/E ratio
|
-5.36
x
|
-2.26
x
|
-1.44
x
|
-1.38
x
|
-1.41
x
|
-1.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
58.2
x
|
88.9
x
|
89.8
x
|
15.9
x
|
5.22
x
|
EV / Revenue
|
-
|
58.2
x
|
88.9
x
|
89.8
x
|
15.9
x
|
5.22
x
|
EV / EBITDA
|
-9,509,103
x
|
-2,412,755
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-6,468,606
x
|
-18,278,022
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.3
x
|
0.98
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
54,641
|
58,974
|
59,835
|
84,501
|
-
|
-
|
Reference price
2 |
15.86
|
5.130
|
3.320
|
2.580
|
2.580
|
2.580
|
Announcement Date
|
3/17/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
5.199
|
2.235
|
2.428
|
13.73
|
41.73
|
EBITDA
|
-91.14
|
-125.4
|
-
|
-
|
-
|
-
|
EBIT
1 |
-94.88
|
-133.8
|
-146.5
|
-139.2
|
-156.5
|
-
|
Operating Margin
|
-
|
-2,574.17%
|
-6,556.87%
|
-5,735.91%
|
-1,140.08%
|
-
|
Earnings before Tax (EBT)
1 |
-95.78
|
-130.8
|
-134.8
|
-129.9
|
-151.4
|
-
|
Net income
1 |
-95.82
|
-130.9
|
-136.7
|
-134.4
|
-139.4
|
-125.9
|
Net margin
|
-
|
-2,518.41%
|
-6,115.12%
|
-5,538.09%
|
-1,015.58%
|
-301.65%
|
EPS
2 |
-2.960
|
-2.270
|
-2.300
|
-1.866
|
-1.834
|
-1.400
|
Free Cash Flow
|
-134
|
-16.55
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-318.37%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
1.058
|
1.396
|
2.224
|
0.521
|
1.72
|
0.099
|
0.148
|
0.268
|
0.855
|
0.6667
|
0.6667
|
0.6667
|
0.55
|
0.55
|
EBITDA
|
-26.92
|
-
|
-
|
-
|
-
|
-
|
-27.62
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-27.97
|
-27.44
|
-31.35
|
-31.74
|
-33.31
|
-32.08
|
-30.86
|
-35.63
|
-43.76
|
-31.31
|
-33.73
|
-35.87
|
-38.37
|
-39.2
|
-41.45
|
Operating Margin
|
-
|
-2,593.19%
|
-2,245.77%
|
-1,427.07%
|
-6,392.71%
|
-1,865.17%
|
-31,168.69%
|
-24,071.62%
|
-16,329.1%
|
-3,661.87%
|
-5,059.97%
|
-5,379.97%
|
-5,754.97%
|
-7,127.27%
|
-7,536.36%
|
Earnings before Tax (EBT)
1 |
-28.87
|
-37.5
|
-30.97
|
-30.72
|
-31.65
|
-30.06
|
-32.34
|
-32.13
|
-40.27
|
-28.06
|
-31.68
|
-33.72
|
-36.47
|
-37.29
|
-39.88
|
Net income
1 |
-28.19
|
-37.51
|
-30.99
|
-30.75
|
-31.68
|
-31.26
|
-33.29
|
-32.72
|
-39.4
|
-28.06
|
-31.68
|
-33.72
|
-36.47
|
-37.29
|
-39.88
|
Net margin
|
-
|
-3,545.65%
|
-2,219.77%
|
-1,382.6%
|
-6,081%
|
-1,817.67%
|
-33,627.27%
|
-22,108.11%
|
-14,700.75%
|
-3,282.11%
|
-4,752.48%
|
-5,058.72%
|
-5,469.97%
|
-6,779.55%
|
-7,250%
|
EPS
2 |
-0.2400
|
-0.6600
|
-0.5400
|
-0.5300
|
-0.5500
|
-0.5300
|
-0.5600
|
-0.5500
|
-0.6600
|
-0.4500
|
-0.4675
|
-0.4800
|
-0.4975
|
-0.5300
|
-0.5233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/16/22
|
8/11/22
|
11/10/22
|
3/16/23
|
5/11/23
|
8/9/23
|
11/9/23
|
3/14/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
213
|
74
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-134
|
-16.6
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-66.1%
|
-37.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-35.2%
|
-28.3%
|
-
|
-
|
-
|
-
|
Assets
1 |
272.1
|
462
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
12.20
|
5.240
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.750
|
0.2400
|
-
|
-
|
-
|
-
|
Capex
|
45
|
30.6
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
588.65%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
2.58
USD Average target price
12.8
USD Spread / Average Target +396.12% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.29% | 218M | | +23.50% | 47.07B | | +47.81% | 42.06B | | -5.16% | 39.98B | | +36.37% | 33.02B | | -7.79% | 27.9B | | +18.06% | 27.63B | | +47.29% | 14.37B | | +41.91% | 13.45B | | -1.02% | 12.03B |
Other Biotechnology & Medical Research
|